Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma Journal Article

   


Authors: Kudelka, M. R.; Richards, A. L.; Friedlander, P.; Wolchok, J. D.; Moy, A. P.; Shoushtari, A. N.
Article Title: Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma
Abstract: Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ/11 mutations. Tebentafusp was recently approved for UM based on improved overall survival in a phase 3 study. We hypothesized that tebentafusp may be active in BN-associated melanoma. Here, we present a case of metastatic BN-associated melanoma with rapid response and ~1 year of disease control on tebentafusp. We also explore molecular and histological features of secondary resistance. Our case highlights that PD-1-resistant melanomas should be screened for GNAQ/11 mutations, as tebentafusp may be a treatment option in this extremely rare disease. © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Keywords: treatment outcome; middle aged; genetics; mutation; case report; melanoma; skin neoplasms; pathology; skin tumor; immunotherapy; drug therapy; blue nevus; guanine nucleotide binding protein alpha subunit; nevus, blue; gtp-binding protein alpha subunits; humans; human; male; female; gnaq protein, human; gtp-binding protein alpha subunits, gq-g11; bispecific t cell engager - bite
Journal Title: Journal for ImmunoTherapy of Cancer
Volume: 12
Issue: 11
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2024-11-01
Start Page: e009609
Language: English
DOI: 10.1136/jitc-2024-009609
PUBMED: 39551602
PROVIDER: scopus
PMCID: PMC11574454
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85209955336&doi=10.1136%2fjitc-2024-009609&partnerID=40&md5=dbb425d463cbee2b3cc9c021c426a193
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledged in the PubMed record and PDF. Corresponding MSK author is Alexander N Shoushtari -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Alexander Noor Shoushtari
    246 Shoushtari
  2. Allison Leigh Richards
    35 Richards
  3. Andrea Primiani Moy
    32 Moy
  4. Matthew Robert Kudelka
    6 Kudelka
Related MSK Work